6 results
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company N.V.
8 May 24
Quarterly report
4:30pm
The weighted average grant date fair value of Company Options, estimated as of the grant date using the Black-Scholes option pricing model, was $ 5.90 , and $ 4.82 per option for options granted during the three months ended March 31, 2024 and 2023, respectively. The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of Company Options exercised during the three months ended March 31, 2024 was $ 8.0 million. No Company Options were exercised in the three months ended March 31, 2023. Weighted average assumptions used to apply this pricing model were as follows:
Three months ended March 31, | ||||||||||
2024 | 2023 | |||||||||
Expected life (years) | 6.1 | 6.1 | ||||||||
Risk-free rate | 3.9 | % | 4.0 | % | ||||||
Volatility | 41.2 | % | 38.5 | % | ||||||
Dividend yield | 0.0 | % | 0.0 | % |
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company N.V.
8 May 24
Quarterly report
4:30pm
The estimated fair value of the derivative earnout liability was determined using Level 3 inputs, other than the Company's share price as a Level 1 input, as no observable market inputs were available. The derivative earnout liability has been measured at fair value using a Black-Scholes pricing model. Given the assumed zero dividend rate and the fact that no strike price exists that would have led to any volatility measure relative to the Company's share price, the fair value of the earnout liability resulting from the Black-Scholes pricing model is entirely driven by the Company’s closing share price as a Level 1 input and the probability of milestone completion as a Level 3 input. As such, the relevant inputs to the fair value of the derivative earnout liability are as follows:
March 31, 2024 | December 31, 2023 | |||||||||
Ordinary Share value (USD) | $ | 23.65 | $ | 11.17 | ||||||
Probability of milestone completion | 40 | % | 40 | % | ||||||
Dividend yield | 0 | % | 0 | % | ||||||
Strike price (USD) | 0.00 | 0.00 |
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company N.V.
28 Feb 24
Annual report
8:00am
The estimated fair value of the Earnout Shares to Participating Shareholders was determined using Level 3 inputs, other than the Company's share price as a Level 1 input, as no observable market inputs were available. The Earnout Shares allocated to Participating Shareholders have been measured at fair value using a Black-Scholes pricing model. Given the assumed zero dividend rate and the fact that no strike price exists that would have led to any volatility measure relative to the Company's share price, the fair value of the Earnout Shares allocated to Participating Shareholders resulting from the Black-Scholes pricing model is entirely driven by the Company’s closing share price as a Level 1 input and the probability of milestone completion as a Level 3 input. As such, the relevant inputs to the fair value of the derivative earnout liability are as follows:
December 31, 2023 | December 31, 2022 | |||||||||
Share value (USD) | 11.17 | 10.90 | ||||||||
Probability of milestone completion | 40 | % | 40 | % | ||||||
Dividend yield | 0 | % | 0 | % | ||||||
Strike price (USD) | 0.00 | 0.00 |
10-K
3kj5o 2ligp2
28 Feb 24
Annual report
8:00am
- Prev
- 1
- Next